POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for myelofibrosis patients with severe anemia
Disease control OngoingThis early-stage study tests an experimental drug called INCB000928, given alone or with a standard medicine (ruxolitinib), for people with myelofibrosis who have low red blood cells (anemia) and need frequent blood transfusions. The goal is to see if the drug is safe and can rai…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
New combo therapy aims to shrink enlarged spleens in bone marrow cancer patients
Disease control OngoingThis study tests whether adding a new drug (pelabresib) to the standard treatment (ruxolitinib) works better than the standard treatment alone for people with myelofibrosis, a rare bone marrow cancer. About 430 adults who have not had prior JAK inhibitor therapy will take part. T…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC